Vilacto Bio Focuses Resources On Pharmaceutical Opportunities for LACTOACTIVE iTHER

COPENHAGEN, Denmark, July 11, 2018 (GLOBE NEWSWIRE) — Vilacto Bio Inc. (OTCQB:VIBI) plans to focus on its new pharmaceutical product, LACTOACTIVE iTHER®, as another potential revenue stream for the company along with its Vilact® brand of skin creams.

“Our Vilact®  brand of skin creams have won several awards around the world, the latest of which was the Buyers Choice Award of Carmen Electra by Vilact® in June,” said Vilacto Bio CEO Gert Anderson. “Now, we will direct our attention to LACTOACTIVE iTHER®.

LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system.

Our own research suggests that LACTOACTIVE iTHER® could contribute significantly to emerging therapies for treating a number of diseases, including cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and vitiligo.  The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.

“Our company’s R&D effort and partnerships development team will now be devoting resources to the further development of LACTOACTIVE iTHER® and the pharmaceutical opportunities it presents,” Anderson said.

With LACTOACTIVE iTHER®, Vilacto Bio plans to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with our refined-colostrum compound “weaponized” as a nanomedicine.  

About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTCQB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.

Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Vilacto Bio Inc.
Fabriksvej 48
4700 Naestved
Denmark

Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com 

Primary Logo

Leave a Comment